Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma

Oncology

Volumn 80, Issue 3-4, 2011, Pages 214-218

  Roubaud, G ^a   Gross Goupil, M ^a   Wallerand, H ^b   De Clermont, H ^c   Dilhuydy, M S ^a   Ravaud, A ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

^b Department of Urology Andrology and Renal Transplantation ^*  (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

Chemotherapy; Doxorubicin; Gemcitabine; Metastatic renal cell carcinoma; National Comprehensive Cancer Network guidelines

Indexed keywords

DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOPENIA; DISEASE FREE SURVIVAL; DRUG EFFICACY; FATIGUE; FEMALE; GRAM NEGATIVE INFECTION; HEART FAILURE; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY DISEASE; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOMATOID RENAL CELL CARCINOMA; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79959650819     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000329078     Document Type: Article

References (20)

1. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841. (Pubitemid 46224183)
2. Grabowski M, Huzarski T, Lubinski J, Sikorski A: Survival in patients with rare subtypes of renal cell carcinoma. BJU Int 2002; 89: 599-600. (Pubitemid 34948307)
3. Mian BM, Bhadkamkar N, Slaton JW, et al: Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167: 65-70. (Pubitemid 34024501)
4. Bannowsky A, Leuschner I, Schiller H, et al: Sarcomatoid renal cell carcinoma: a rare and aggressive variation of primary renal cell carcinoma (in German). Urologe A 2007; 46: 406-411. (Pubitemid 46623436)
5. Escudier B: Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007; 67: 1257-1264. (Pubitemid 46879093)
6. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 2376-2381. (Pubitemid 34441667)
7. Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20: 303-321. (Pubitemid 23154480)
8. Culine S, Bekradda M, Terrier-Lacombe MJ, Droz JP: Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy? Eur Urol 1995; 27: 138-141.
9. Rohde D, De Mulder PH, Weissbach L, Osieka R, Blatter J, Jakse G: Experimental and clinical efficacy of 2', 2'-difluorodeoxycytidine (gemcitabine) against renal cell carcinoma. Oncology 1996; 53: 476-481. (Pubitemid 26388389)
10. Porta C, Zimatore M, Imarisio I, et al: Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution phase II study. Cancer 2004; 100: 2132-2138. (Pubitemid 38580331)
11. Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM: Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18: 2419-2426. (Pubitemid 30415829)
12. Bangalore N, Bhargava P, Hawkins MJ, Bhargava P: Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol 2001; 12: 271-274. (Pubitemid 32223881)
13. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101: 1545-1551. (Pubitemid 39318900)
14. Motzer RJ, Agarwal N, Beard C, et al: NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009; 7: 618-630.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
16. Haas NB, Manola J, Pins M, et al: A phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2011, E-pub ahead of print.
17. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. (Pubitemid 46089672)
18. Golshayan AR, George S, Heng DY, et al: Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27: 235-241.
19. Michaelson MD, Iliopoulos O, McDermott DF, McGovern FJ, Harisinghani MG, Oliva E: Case records of the Massachusetts General Hospital: case 17-2008-a 63-year-old man with metastatic renal-cell carcinoma. N Engl J Med 2008; 358: 2389-2396. (Pubitemid 351749165)
20. Saylor PJ, Michaelson MD: New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 2009; 7: 645-656.